In August 2025, Sanofi acquired the rights to develop and commercialize Redemplo in Greater China from Visirna Therapeutics, a majority-owned subsidiary of Arrowhead Pharmaceuticals.

Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndromeUnderscores Sanofi's long-term commitment to ...

CareMed®, an independent specialty pharmacy, has been selected as a pharmacy partner by Cytokinetics for MYQORZO™ (aficamten), indicated for the treatment of adults with symptomatic obstructive ...

BMY reports positive late-stage data for Camzyos in adolescents with oHCM, expanding its cardiovascular outlook amid pipeline ...

Unlike traditional transplant approaches, the goal is not to permanently replace a failing liver, but to create a temporary, ...

NEW HYDE PARK, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- CareMed (R) , an independent specialty pharmacy, has been selected as a pharmacy partner by Cytokinetics for MYQORZO (TM) (aficamten), indicated ...

Orsini, a leader in rare disease pharmacy solutions, announced today that it is a specialty pharmacy partner for Cytokinetics's MYQORZOtm (aficamten), an FDA-approved cardiac myosin inhibitor ...

A research team led by Zhiping Weng, Ph.D., and Jill Moore, Ph.D."18, at UMass Chan Medical School, has nearly tripled the ...

SCOUT-HCM demonstrated the superiority of Camzyos on the primary endpoint and multiple secondary endpointsThe overall safety results in this study were consistent with the established safety profile ...

Doctors often say labs look “normal.” Dr. Mark Hyman explains why that doesn’t always reflect wellness, and what early ...